Back

Rapid, Comprehensive Methylation-Based Classification of Hematologic Malignancies by Nanopore Sequencing

Achterberg, T.; Vermeulen, C.; van der Ent, H.; Jongmans, M.; Cammel, K.; de Ruijter, E.; Groenewegen, N.; Kranenburg, C.; van Tuil, M.; Waanders, E.; Parihar, M.; Islam, R.; Aijaz, J.; Goemans, B.; Calkoen, F.; van der Sluis, I.; den Boer, M. L.; Boer, J. M.; de Haas, V.; Triche, T.; Alexander, T. B.; Wang, J. R.; Bhakta, N.; Pieters, R.; Kester, L.; Tops, B.; de Ridder, J.

2026-07-02 hematology
10.64898/2026.07.02.26356825 medRxiv
Show abstract

Hematologic malignancies are diagnosed through a fragmented, sequential workup of morphology, immunophenotyping, cytogenetics, and molecular testing that can take days to weeks and is unavailable at many centers. DNA methylation profiling has transformed central nervous system tumor diagnosis, yet hematologic classifiers have remained confined to narrow acute leukemia panels. Here we present Lamprey, a deep-learning methylation classifier spanning 86 hematologic malignancy entities, trained on a reference cohort of 8,544 patients and deployed directly from nanopore sequencing. A depth-aware training framework allows confident classification from the first minutes of a run. Against blinded integrated reference diagnoses across retrospective, external, and prospective cohorts, Lamprey exceeded 98% accuracy among classified cases. Lamprey reaches a confident call within minutes, and cost as little as $82 per sample. Lamprey consolidates a sequential diagnostic workup into a single, rapid, same-day molecular readout.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.